<?xml version="1.0" encoding="UTF-8"?>
<p>Although COVID-19-related conjunctivitis is a self-limiting disease, efforts to reduce transmission in the community are equally vital. Well-structured, randomized, controlled trials are required to validate the use of the abovementioned drugs for containment of the current pandemic and future epidemics if any. Pending these trials, the use of commonly available BAK containing medications such as antibiotic and tears substitutes with minimal side effects may be advocated to suspected conjunctivitis cases, considering the mammoth task of controlling the ongoing pandemic.</p>
